Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013-2018.
Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013-2018.
复制标题
利奈唑胺用于治疗耐多药结核病，结核病卓越中心，美国，2013-2018。
DOI：
10.1016/j.jctube.2020.100201
复制
发表时间：
2021-03
影响因子：
2
通讯作者：
Goswami ND
中科院分区：
文献类型：
--
作者：
McDowell A;Haas M;Seaworth B;Wilson JW;Patrawalla A;Haley C;Lauzardo M;de Bruyn M;Goswami ND
2019年，世界卫生组织发布的指南反映了耐多药结核病（MDR-TB）管理的重大变化-优先考虑氟喹诺酮类，贝达喹啉和利奈唑胺（LZD），而不再强调以前青睐的注射剂。在某些情况下，利奈唑胺的使用与胃肠道不耐受、线粒体毒性和显著的药物相互作用相关。疾病预防控制中心的结核病消除司支持一个区域结核病卓越中心网络，该中心为医疗保健提供者提供医疗咨询。咨询记录在一个医疗咨询数据库（MCD）中，以便对管理问题和建议进行评价。我们描述了在美国利奈唑胺用于耐多药结核病的特定临床询问和回复的范围。在美国使用利奈唑胺治疗耐多药结核病时，提供者和患者面临的主要挑战是什么？我们查询了2013年1月1日至2018年12月31日归类为“MDR/XDR-TB”的MCD咨询。仅纳入了利奈唑胺特定咨询;排除了不完整和重复的条目，以及历史上或理论上引用利奈唑胺的条目。评估亚组特征（例如，中心、年份、供应商类型）。通过归纳主题分析，制定了描述性编码方案。2013-2018年，在1889例关于MDR/XDR-TB的咨询中，934例MDR-TB咨询参考了利奈唑胺; 137例符合入选标准，占每年MDR-TB咨询的4%至10%。出现了四个主要主题：不良反应（71.5%）;由于合并症或合并用药而对利奈唑胺使用的担忧（15.3%）;剂量调整（8.8%）;以及监测和维持物流（4.4%）。在6年期间，利奈唑胺咨询量始终超过每年所有咨询量的4%，这表明使用利奈唑胺管理耐多药结核病的提供者需要获得专家意见。虽然这只是美国耐多药结核病的一个快照，但本评价总结了主要提供者对特定不良反应的担忧，并强调了对利奈唑胺给药和毒性管理的循证指南的需求。
In 2019, the World Health Organization released guidelines reflecting major changes in multidrug-resistant tuberculosis (MDR-TB) management—prioritizing fluoroquinolones, bedaquiline, and linezolid (LZD) while de-emphasizing previously favored injectable agents. In some cases, linezolid use is associated with gastrointestinal intolerance, mitochondrial toxicity, and significant drug interactions. CDC’s Division of Tuberculosis Elimination supports a network of regional TB Centers of Excellence, which provide medical consultation to healthcare providers. Consultations are documented in a medical consultation database (MCD) enabling evaluation of management questions and recommendations. We describe the scope of clinical inquiries and responses specific to linezolid use for MDR-TB in the US. What are the major themes of provider and patient challenges regarding the use of linezolid for the treatment of MDR-TB in the US? We queried MCD consults categorized as “MDR/XDR-TB” from 1/1/2013 to 12/31/2018. Only linezolid-specific consultations were included; incomplete and duplicate entries were excluded as were those citing linezolid historically or theoretically. Subgroup characteristics were assessed (e.g., Center, year, provider type). A descriptive coding scheme was developed through inductive thematic analysis. In 2013–2018 of the 1889 consults regarding MDR/XDR-TB, 934 MDR-TB consults referenced linezolid; 137 met inclusion criteria, representing between 4 and 10% of MDR-TB consults annually. Four main themes emerged: adverse effects (71.5%); concerns about linezolid use due to co-morbidities or concurrent medication use (15.3%); dosing adjustments (8.8%); and monitoring and maintenance logistics (4.4%). Linezolid consults consistently exceeded 4% of all consults annually over the 6-year period, suggesting a need for access to expert opinion for providers using linezolid to manage MDR-TB. While only a snapshot of MDR-TB in the US, this evaluation summarizes major provider concerns regarding particular adverse effects, and highlights a need for evidence-based guidance regarding linezolid dosing and toxicity management.
登录
查看更多内容
影响因子：
158.5
作者：
Conradie, Francesca;Diacon, Andreas H.;Spigelman, Melvin
通讯作者：
Spigelman, Melvin
DOI：
10.1164/rccm.201909-1874st
发表时间：
2019-11-15
影响因子：
24.7
作者：
Nahid, Payam;Mase, Sundari R.;Seaworth, Barbara
通讯作者：
Seaworth, Barbara
影响因子：
11.8
作者：
Lawrence, KR;Adra, M;Gillman, PK
通讯作者：
Gillman, PK
影响因子：
2.9
作者：
Heysell SK;Moore JL;Peloquin CA;Ashkin D;Houpt ER
通讯作者：
Houpt ER
DOI：
10.5588/ijtld.17.0468
发表时间：
2017-11-01
影响因子：
4
作者：
Reuter, A.;Tisile, P.;Furin, J.
通讯作者：
Furin, J.